| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
111,993,000 |
| Market
Cap: |
4.93(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.035 - $13.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evelo Biosciences is discovering and developing a class of medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The target cells in the small intestine play a role in governing human immune, metabolic and neurologic systems. Co.'s product candidates are orally delivered pharmaceutical preparations of naturally occurring, specific single strains of microbes or microbial extracellular vesicles. Co.'s product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Additional product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,411,255 |
33,202,348 |
| Total Buy Value |
$0 |
$0 |
$12,499,999 |
$53,074,995 |
| Total People Bought |
0 |
0 |
1 |
4 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
8,249 |
41,724 |
218,687 |
| Total Sell Value |
$0 |
$2,723 |
$98,502 |
$120,853 |
| Total People Sold |
0 |
4 |
4 |
5 |
| Total Sell Transactions |
0 |
4 |
10 |
15 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mchale Duncan |
Chief Medical Officer |
• – – |
2023-11-08 |
4 |
AS |
$0.33 |
$1,024 |
D/D |
(3,103) |
16,984 |
|
-83% |
|
| Thorell Marella |
Chief Financial Officer |
• – – |
2023-11-08 |
4 |
AS |
$0.33 |
$598 |
D/D |
(1,811) |
22,259 |
|
-83% |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-11-08 |
4 |
AS |
$0.33 |
$1,044 |
D/D |
(3,163) |
25,732 |
|
-83% |
|
| Gill Simba |
President & CEO |
• • – |
2023-11-08 |
4 |
AS |
$0.33 |
$57 |
D/D |
(172) |
17,758 |
|
-83% |
|
| Mchale Duncan |
Chief Medical Officer |
• – – |
2023-11-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
20,087 |
|
- |
|
| Thorell Marella |
Chief Financial Officer |
• – – |
2023-11-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
24,070 |
|
- |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-11-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,625 |
28,895 |
|
- |
|
| Gill Simba |
President & CEO |
• • – |
2023-11-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,172 |
17,930 |
|
- |
|
| Gill Simba |
President & CEO |
• • – |
2023-09-28 |
4 |
AS |
$3.94 |
$7,864 |
D/D |
(1,996) |
16,758 |
|
-99% |
|
| Gill Simba |
President & CEO |
• • – |
2023-09-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
18,754 |
|
- |
|
| Gill Simba |
President & CEO |
• • – |
2023-08-08 |
4 |
AS |
$9.51 |
$3,252 |
D/D |
(342) |
3,754 |
|
-100% |
|
| Thorell Marella |
Chief Financial Officer |
• – – |
2023-08-08 |
4 |
AS |
$9.51 |
$19,058 |
D/D |
(2,004) |
9,069 |
|
-100% |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-08-08 |
4 |
AS |
$9.51 |
$29,747 |
D/D |
(3,128) |
16,624 |
|
-100% |
|
| Mchale Duncan |
Chief Medical Officer |
• – – |
2023-08-08 |
4 |
AS |
$9.51 |
$32,657 |
D/D |
(3,434) |
7,941 |
|
-100% |
|
| Gill Simba |
President & CEO |
• • – |
2023-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,171 |
4,096 |
|
- |
|
| Thorell Marella |
Chief Financial Officer |
• – – |
2023-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,073 |
|
- |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,625 |
19,752 |
|
- |
|
| Mchale Duncan |
Chief Medical Officer |
• – – |
2023-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,375 |
|
- |
|
| Horizon Technology Finance Corp |
10% Owner |
– – • |
2023-07-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,164,502 |
|
-87% |
|
| Afeyan Noubar |
|
– – • |
2023-07-11 |
4 |
B |
$2.31 |
$12,499,999 |
I/I |
5,411,255 |
3,931,685 |
0.01 |
-87% |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-05-23 |
4 |
AS |
$0.14 |
$3,201 |
D/D |
(22,571) |
262,557 |
|
33% |
|
| Mchale Duncan |
Chief Medical Officer |
• – – |
2023-05-08 |
4 |
AS |
$0.13 |
$8,375 |
D/D |
(66,730) |
97,516 |
|
103% |
|
| Bodmer Mark |
CSO, President of R&D |
• – – |
2023-05-08 |
4 |
AS |
$0.13 |
$8,536 |
D/D |
(68,014) |
285,128 |
|
103% |
|
| Thorell Marella |
Chief Financial Officer |
• – – |
2023-05-08 |
4 |
AS |
$0.13 |
$4,836 |
D/D |
(38,531) |
91,469 |
|
103% |
|
| Gill Simba |
President & CEO |
• • – |
2023-05-08 |
4 |
AS |
$0.13 |
$444 |
D/D |
(3,537) |
58,512 |
|
103% |
|
62 Records found
|
|
Page 1 of 3 |
|
|
